Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3515-3525

  Soudja, Saïdi M ^a,b,c   Wehbe, Maria ^a,b,c   Mas, Amandine ^a,b,c   Chasson, Lionel ^a,b,c   De Tenbossche, Céline Powis ^d   Huijbers, Ivo ^d,e   Van Den Eynde, Benoît ^d   Schmitt Verhulst, Anne Marie ^a,b,c  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CELL SPECIFICITY; CELLULAR IMMUNITY; GENE DELETION; GENE EXPRESSION; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOCOMPETENCE; INFLAMMATION; INOCULATION; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH17 CELL; TH2 CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE DELETION; GENES, RAS; GENES, TUMOR SUPPRESSOR; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; RAS PROTEINS;

EID: 77951708030     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4354     Document Type: Article

References (50)

1. + T cells in the circulation but not in the tumor site. J Immunol 2006;177:1670-1678
2. Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol 2007;19:121-127
3. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
4. + T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003;63:2535-2545
5. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005;437:141-146
6. + T cell cytotoxicity and cancer. Semin Cancer Biol 2006;16:124-136
7. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
8. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-174
9. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425, author reply 6.
10. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444
11. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461
12. Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009;16:55-66.
13. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907
14. Willimsky G, Czeh M, Loddenkemper C, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008;205:1687-1700
15. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-423
16. Uyttenhove C, Godfraind C, Lethe B, et al. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer 1997;70:349-356
17. Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 2004;4:688-698
18. Huijbers IJ, Krimpenfort P, Chomez P, et al. An inducible mouse model of melanoma expressing a defined tumor antigen. Cancer Res 2006;66:3278-3286
19. Shanker A, Auphan-Anezin N, Chomez P, Giraudo L, Van den Eynde B, Schmitt-Verhulst AM. Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR. J Immunol 2004;172:5069-5077
20. Shanker A, Verdeil G, Buferne M, et al. CD8 T cell help for innate antitumor immunity. J Immunol 2007;179:6651-6662
21. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-2182
22. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997;11:2822-2834
23. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
24. Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006;108:812-820
25. Nakayama T, Mutsuga N, Tosato G. Effect of fibroblast growth factor 2 on stromal cell-derived factor 1 production by bone marrow stromal cells and hematopoiesis. J Natl Cancer Inst 2007;99:223-235
26. Awasthi A, Kuchroo VK. IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol 2009;10:568-570
27. + T cells display enhanced antitumor immunity. Blood 2009;114:596-599
28. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009;15:1931-1939
29. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008;205:585-594
30. Meixner A, Zenz R, Schonthaler HB, et al. Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat Cell Biol 2008;10:1003-1011
31. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964
32. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005;202:931-939
33. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009;229:67-87.
34. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-1544
35. Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-2873 (Pubitemid 38500627)
36. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37. (Pubitemid 43053650)
37. Prehn RT. Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res 1994;54:908-914
38. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-1218 (Pubitemid 47530639)
39. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66:11238-11246 (Pubitemid 46009952)
40. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91-102.
41. Ambrosino E, Spadaro M, Iezzi M, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006;66:7734-7740 (Pubitemid 44289233)
42. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10:294-298 (Pubitemid 38667621)
43. Guarda G, Dostert C, Staehli F, et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009;460:269-273
44. Safarians S, Rivera SP, Sternlicht MD, Naeim F, Barsky SH. Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression. Am J Pathol 1997;150:949-962 (Pubitemid 27106167)
45. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009;106:6742-6747
46. Xue Y, Religa P, Cao R, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A 2008;105:18513-18518
47. Sawanobori Y, Ueha S, Kurachi M, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008;111:5457-5466
48. Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2007;2:e594. (Pubitemid 351266390)
49. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000;60:5012-5016
50. Powell DJ Jr., Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006;177:6527-6539